AstraZeneca: EU body backs expanded use of Lynparza
(CercleFinance.com) - European regulators have recommended a new indication for AstraZeneca and Merck's Lynparza as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer.
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Lynparza tablets as a maintenance treatment for adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following chemotherapy.
Lynparza is currently approved in 64 countries, including in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Lynparza tablets as a maintenance treatment for adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following chemotherapy.
Lynparza is currently approved in 64 countries, including in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.
Copyright (c) 2019 CercleFinance.com. All rights reserved.